Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/135497
Title: Hepatitis C services at harm reduction centres in the European Union: a 28-country survey
Author: Pericàs, Juan M.
Bromberg, Daniel J.
Ocampo, Denise
Schatz, Eberhard
Wawer, Iwona
Wysocki, Piotr
Safreed Harmon, Kelly
Lazarus, Jeffrey V.
Keywords: Hepatitis C
Països de la Unió Europea
European Union countries
Issue Date: 21-Mar-2019
Publisher: BioMed Central
Abstract: Background: In the context of the WHO’s 2016 Viral Hepatitis Strategy and the introduction of treatment that can cure more than 95% of cases with hepatitis C virus (HCV) infection, the European Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) undertook a study in the member states of the European Union (EU). It aimed to determine service providers’ understanding of the current services in their respective countries and the barriers experienced by PWID in accessing HCV testing, care and treatment services in their country. Methods: In 2017, 38 purposively selected harm reduction service providers completed a 26-item Englishlanguage online survey addressing the availability, accessibility and funding of HCV services at harm reduction centres. HCV-related data and reported findings were extracted by country or by responding organization. Results: Responses were received from all EU member states. Respondents from 23 countries reported that HCV tests are offered by harm reduction services in their countries, and eight countries reported that addiction specialists in their countries are able to prescribe HCV therapy. Almost half of the respondents (45%) said that their respective organizations had established referral systems with centres providing HCV treatment. Conclusions: Not all EU member states have harm reduction services that provide HCV tests, and many do not have established referral systems with treatment providers. Moreover, the inability of addiction specialists to prescribe HCV treatment points to missed opportunities to make treatment more accessible. Further, discrepancies were noted between the available HCV services and stakeholders’ knowledge about their availability.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/s12954-019-0290-x
It is part of: Harm Reduction Journal, 2019, vol. 16, num. 20
URI: http://hdl.handle.net/2445/135497
Related resource: http://dx.doi.org/ 10.1186/s12954-019-0290-x
ISSN: 1477-7517
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
PericasJM_Harm_Reduct_J_2019.pdf625.33 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons